Scopus Açık Erişimli Yayınlar

Permanent URI for this collectionhttps://hdl.handle.net/11727/10760

Browse

Filters

20212

Settings

Author: search.filters.author.Gumus, Hatice Halesearch.filters.applied.f.language: search.filters.language.eng

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers
    (2021) Gumus, Hatice Hale; Odemis, İlker; Aliska, Hikmet Eda; Karsli, Asli; Kara, Sibel; Ozkale, Murat; Gul, Eylem; 0000-0001-9071-9606; 0000-0001-9060-3195; 0000-0003-2638-0163; 34909957; AAJ-2108-2021; AAE-2282-2021
    OBJECTIVE: This study aims to investigate the antibody response and the side effects of the two-dose inactive SARS-CoV-2 vaccine (CoronaVac, Sinovac, China) among a health care worker population in Turkey. METHODS: This study was a prospective, cross-sectional, single-center study conducted between December 16, 2020, and March 15, 2021. We evaluated the side effects from a questionnaire, and anti-spike immunoglobulin G response to the vaccine (0- and 28-day schedule) using an enzyme-linked immunosorbent assay. RESULTS: A total of 94 of 184 health care workers completed this study. The percentages of participants who were seronegative at baseline and achieved to the seropositivity were 21.3 and 97.9%, respectively, on day 21 after vaccinations. The seropositivity was predominantly detected in 31-45 years of the age group (55.4%, p=0.636), normal body mass index (47.8%, p=0.999), nonsmokers (64.1%, p=0.999), those without any comorbidities (73.9%, p=0.463), and those without any side effects (70.2%, p=0.256). The frequencies of overall side effects within seven days after the first and second doses of CoronaVac were 37.2 and 28.7%, respectively. The most common side effects was localized pain at the injection site (15.7 and 11.6%, respectively). CONCLUSIONS: We found that vaccination by two-dose CoronaVac could elicit a specific humoral response, and it was well tolerated in health care workers. The high seropositivity developed after the second dose attracted attention. Our study will be useful in terms of showing short-term immunity and side effects.
  • No Thumbnail Available
    Item
    Evaluation of Clinical Symptoms, Laboratory Findings, Radiological Characteristics, and Treatments of Adult Patients with Severe COVID-19 Pneumonia
    (2021) Kurekci, Yesim; Gumus, Hatice Hale; Ezirmik, Elif; 0000-0001-9071-9606; AAJ-2108-2021
    Introduction: In this study, it was aimed to retrospectively evaluate the clinical course, laboratory findings and radiological features of patients with severe Coronavirus disease-2019 (COVID-19) pneumonia in a 200-bed secondary state hospital. Materials and Methods: Male and non-pregnant female patients older than 18 years who were hospitalized with the diagnosis of COVID-19 pneumonia between 01.04.2020-01.07.2020 were included in our study. Severe pneumonia was defined as the presence of tachypnea (>30 breaths/ min) and/or hypoxia (SpO2 <90% room air) and/or bilateral diffuse ground-glass infiltrations. Conformity of continuous data to normal distribution was evaluated with Kolmogorov-Smirnov and Shapiro-Wilk tests. In the analysis of the relationship between laboratory parameters and mortality, independent groups t-test was used for parametric data and Mann-Whitney U test was used for non-parametric data. Results: Sixty two (60.8%) of the patients were male, with a mean age of 60.2 +/- 16.1 years (n=102). Of the study group 76.5% had at least one or more comorbid diseases. The most common comorbidities were hypertension (60.3%), diabetes mellitus (42.3%) and coronary artery disease (26.9%). The most common symptoms observed in patients at the time of admission were cough (n=63, 61.8%), dyspnea (n=57, 55.9%), fever (n=33, 32.4%) and malaise (n=22, 21.6%). Severe acute respiratory syndrome-Coronavirus-2 polymerase chain reaction test was positive in 68% (n=70) of the patients. Blood culture was taken from 42.3% of the patients who were admitted with the complaint of fever and there was no detected culture growth. During the hospitalization period, the rate of patients who received any of the antibiotic treatments including azithromycin, clarithromycin, moxifloxacin was 90.2% and 66.7% (n=68) of them were treated with azithromycin. Of the patients 42.2% (n=43) required treatment in the intensive care unit. A favorable clinical response was observed in 74.5% (n=77) of the patients and nine of these patients were discharged with partial recovery and recommendation for home oxygen support therapy. The mortality rate was 24.5% (n=25). The mean of lactate dehydrogenase level and the mean urea level were higher in the group with mortality (p <= 0.001). Conclusion: Despite the low rates of bacterial coinfection and/or secondary bacterial infection in COVID-19, frequently given antibiotic treatments contribute to the problem of antimicrobial resistance, creating a serious public health problem and causing an economic burden. Large-scale randomized controlled trials are required for treatment protocols of which potential benefits have not yet been proven.